ストックスクリーナーアプリを入手
1.435
10.77%
0.135
前日終値:
$1.30
開ける：
$1.3
24時間の取引高:
530.14K
Relative Volume:
0.46
時価総額：
$89.35M
収益：
-
当期純損益:
$-73.79M
株価収益率:
-0.7799
EPS:
-1.84
ネットキャッシュフロー:
$-77.44M
1週間 パフォーマンス:
+25.22%
1か月 パフォーマンス:
-65.88%
6か月 パフォーマンス:
+26.32%
1年 パフォーマンス:
-17.24%
1日の値動き範囲:
$1.285
$1.46
1週間の範囲:
$1.13
$1.46
52週間の値動き範囲:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
PYXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.435 | 80.94M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.20 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.01 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.08 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
810.40 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.04 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Is Pyxis Oncology Inc. stock recession proofExit Point & AI Forecasted Entry and Exit Points - Улправда
Will Pyxis Oncology Inc. stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - Defense World
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology sees cash runway into 4Q26 - MSN
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Bull vs Bear & Long-Term Safe Return Strategies - DonanımHaber
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk - marketscreener.com
Pyxis plummets following phase 1 data on candidate for head and neck cancer - MSN
Is Pyxis Oncology Inc. stock a contrarian buy2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS) - Defense World
Pyxis Oncology reports positive data for head and neck cancer drug By Investing.com - Investing.com South Africa
Fed Meeting: Is Pyxis Oncology Inc. stock positioned well for digital economyMarket Trend Report & AI Enhanced Trade Execution Alerts - Улправда
Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com Australia
Pyxis Oncology stock falls as RBC cuts price target on complex trial data By Investing.com - Investing.com South Africa
Pyxis Oncology reports positive data for head and neck cancer drug - Investing.com Nigeria
Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative
Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2025-12-18 - Seeking Alpha
Transcript : Pyxis Oncology, Inc.Special Call - marketscreener.com
Pyxis Oncology stock plummets after early-stage cancer drug data By Investing.com - Investing.com South Africa
Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com
Pyxis Oncology’s Stock Moves: Time for Investors to Act? - timothysykes.com
PYXS: MICVO shows strong efficacy and safety in R/M HNSCC, both as monotherapy and with KEYTRUDA - TradingView — Track All Markets
Pyxis Oncology Reports Strong MICVO Data and Financing - TipRanks
Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView — Track All Markets
PYXS FinancialsIncome Statement - Quiver Quantitative
Pyxis Oncology (PYXS) shows promising MICVO results and extends cash runway - Stock Titan
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
0.70%
大文字化:
|
ボリューム (24 時間):